Vamsi Pharma Private Limited

Vamsi Pharma Private Limited, established on July 16, 2015, is a private pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the development and manufacturing of orally inhaled and nasal drug products (OINDP), with a particular emphasis on Dry Powder Inhalers (DPI). Operating under Corporate Identification Number (CIN) U24100TG2015PTC099814, Vamsi Pharma is classified as a private limited company. The authorized capital stands at ₹17.50 crore, with a paid-up capital of ₹15.63 crore. As of April 8, 2024, the company employed 32 professionals. The registered office is located at Sy. No. 707 & 708, Nandi Gama Village, Mekagudem GP, Kothur Mandal, Hyderabad, Telangana, 509228.

Vamsi Pharma operates a WHO-GMP certified manufacturing facility situated in Hyderabad, Telangana, India. The plant specializes in the production of orally inhaled and nasal drug products, focusing on Dry Powder Inhalers (DPI). The facility is equipped to handle the entire product development lifecycle, from ideation and research to formulation, regulatory compliance, scale-up, and market launch.

The leadership team at Vamsi Pharma comprises several key individuals:

• Ravindra Nandlal Purohit: Managing Director since July 16, 2015.

• Keshava Reddy Madana: Director since July 16, 2015.

• Pratap Reddy Linga Reddy Gaddam: Director since July 16, 2015.

• Madhusudan Reddy Padira: Director since July 16, 2015.

• Prashant Nalinaksh Garg: Director since September 2, 2022.

The company secretary is Venkatachalam Seetharaman, appointed on September 21, 2024.

Vamsi Pharma's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, indicate a total export value of $2.5 million USD across 49 shipments, primarily in the respiratory therapeutic category. The top three exported products are Fluticasone ($900K), Salmeterol ($900K), and Tiotropium ($650K). These products are finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. Notably, Salmeterol holds a 1.2% market share, ranking fifth, while Tiotropium holds a 1.0% market share, ranking third. The company's focus on respiratory products aligns with global health priorities, particularly in managing asthma and chronic obstructive pulmonary disease (COPD).

Vamsi Pharma's export data indicates a concentration in the respiratory therapeutic category, with no diversification into other therapeutic areas. This focus suggests a strategic emphasis on respiratory treatments, potentially limiting exposure to market fluctuations in other therapeutic segments. The company's export activities are primarily directed towards markets with established demand for respiratory medications, which may include regions in Africa, Latin America, and Southeast Asia. However, specific market penetration details are not available in the provided data.

Vamsi Pharma's export strategy is highly concentrated, with the top five products accounting for 100% of exports. This indicates a focused approach on a limited product range, which can lead to increased vulnerability to market fluctuations and regulatory changes affecting these specific products. The company's strategic direction appears to be centered on respiratory treatments, leveraging its expertise in this therapeutic area. While this focus allows for specialization, it may also pose risks associated with market concentration.

Specific details regarding Vamsi Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided data. Given the company's focus on respiratory products, it is plausible that they have pursued regulatory approvals in markets such as the United States. However, without explicit information, a comprehensive assessment of their FDA status cannot be made.

Vamsi Pharma's manufacturing facility is WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification underscores the company's commitment to maintaining high-quality standards in its production processes. Specific details regarding EU GMP certificates or EDQM status are not available in the provided data.

Vamsi Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facility is located in Hyderabad, Telangana, and is registered under the jurisdiction of the Hyderabad Regional Office of the CDSCO. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not available in the provided data.

No specific information regarding Form 483 observations, warning letters, or import alerts related to Vamsi Pharma is available in the provided data. The absence of such information suggests that the company may not have faced significant regulatory challenges in recent years.

Vamsi Pharma operates in the respiratory therapeutic category, exporting products such as Fluticasone, Salmeterol, and Tiotropium. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. While specific market share data for competitors is not available, the respiratory market is competitive, with several established players offering similar products. Vamsi Pharma's focus on respiratory treatments positions it within a niche segment, potentially reducing direct competition but also limiting market opportunities.

Vamsi Pharma's key differentiators include its specialized focus on respiratory treatments, particularly in the development and manufacturing of Dry Powder Inhalers (DPI). The company's WHO-GMP certified facility and its "Concept to Commissioning" model for product development highlight its commitment to quality and comprehensive service offerings. This integrated approach allows Vamsi Pharma to deliver innovative and cost-effective inhalation products, catering to the evolving demands of global healthcare markets.

Vamsi Pharma's strategic direction is centered on the development and manufacturing of respiratory treatments, with a particular emphasis on Dry Powder Inhalers (DPI). The company's focus on this niche segment allows for specialization and expertise in pulmonary drug delivery technologies. While this concentrated approach may limit exposure to other therapeutic areas, it also positions Vamsi Pharma as a specialized player in the respiratory market, potentially offering unique value propositions to partners and clients.

Vamsi Pharma's export data indicates a total export value of $2.5 million USD across 49 shipments, primarily in the respiratory therapeutic category. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. This suggests a focused approach on a limited product range, which can lead to increased vulnerability to market fluctuations and regulatory changes affecting these specific products. The company's WHO-GMP certified facility and its "Concept to Commissioning" model for product development highlight its commitment to quality and comprehensive service offerings. However, the lack of diversification in its product portfolio may pose risks associated with market concentration.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. This can be verified through the FDA's official website or by contacting the FDA directly.

• WHO-GMP Certification: Ensure that the manufacturing facility holds a valid World Health Organization Good Manufacturing Practices (WHO-GMP) certification. This can be verified by contacting the World Health Organization or the national regulatory authority in India.

• EU GMP Certification: If exporting to the European Union, verify that the manufacturing facility complies with European Union Good Manufacturing Practices (EU GMP). This can be confirmed through the European Medicines Agency (EMA) or the national regulatory authority.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications related to quality management systems. These can be verified through the International Organization for Standardization or the certifying body.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm that the products have the necessary approvals